AR012427A1 - MODIFIED FTN-ALPHA MOLECULES, CODED DNA AND VACCINES INCLUDING SUCH FTN-ALPHA AND DNA MODIFICATION - Google Patents
MODIFIED FTN-ALPHA MOLECULES, CODED DNA AND VACCINES INCLUDING SUCH FTN-ALPHA AND DNA MODIFICATIONInfo
- Publication number
- AR012427A1 AR012427A1 ARP980101722A ARP980101722A AR012427A1 AR 012427 A1 AR012427 A1 AR 012427A1 AR P980101722 A ARP980101722 A AR P980101722A AR P980101722 A ARP980101722 A AR P980101722A AR 012427 A1 AR012427 A1 AR 012427A1
- Authority
- AR
- Argentina
- Prior art keywords
- alpha
- human
- modified
- tnf alpha
- molecule
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000008836 DNA modification Effects 0.000 title 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 9
- 102000057041 human TNF Human genes 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una molécula de TNF alfa humano modificada capaz de incitar anticuerpos neutralizantes hacia el TNF alfa humano del tipo sin cultivar, luego de laadministracion de dicha molécula de TNF alfa modificada a un huésped humano, donde por lo menosu n fragmento de péptido de la molécula de TNF alfa humanoha sido sustituido por un péptido como mínimo que, segun se sabe, contiene un epitopo de células T inmuno-dominante o una forma truncada de dicha moléculaque contiene un epitopo inmuno-dominan te, y una o ambas regiones flanqueadoras de la molécula de TNF alfa humano que comprende por lo menos un epitopo decélula B de TNF alfa, donde la sustitucion introduce un cambio sustancial en la secuencia de aminoácidos de la lámina betafrontal, en uno cualesquiera delos bucles conectores y/o en uno cualesquiera de los filamentos B, I o D de la lámina beta posterior. Las moléculas de TNF alfa humano modificadas o el ADNque las codifica pueden formularse como vacunas contra el TNFalfa, opcionalmente con adyuvantes farmacéuticamente aceptables, para la prevenciono el tratamiento de enfermedades inflamatorias cronicas, tales como artritis reumatoide y enfermedades inflamatorias de los intestinos, cáncer,esclerosisdiseminada, diabetes, psoriasis, osteoporosis o asma. Los fluidos humanos pueden ser sometidos a prueba para detectar la presencia de TNF alfa porcontacto con una composicion que contenga al TNF alfa modificado.A modified human TNF alpha molecule capable of inducing neutralizing antibodies to human TNF alpha of the uncultivated type, after administration of said modified TNF alpha molecule to a human host, where at least one peptide fragment of the TNF molecule Human alpha has been replaced by at least one peptide known to contain an immuno-dominant T-cell epitope or a truncated form of that molecule containing an immuno-dominant epitope, and one or both flanking regions of the TNF molecule. Human alpha comprising at least one TNF alpha B cell epitope, where the substitution introduces a substantial change in the amino acid sequence of the betafrontal lamina, in any one of the connecting loops and / or in any one of the B, I filaments or D of the posterior beta lamina. Modified human TNF alpha molecules or the DNA encoding them can be formulated as vaccines against TNFalpha, optionally with pharmaceutically acceptable adjuvants, to prevent the treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases, cancer, disseminated sclerosis , diabetes, psoriasis, osteoporosis or asthma. Human fluids can be tested for the presence of TNF alpha by contacting with a composition containing the modified TNF alpha.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK41897 | 1997-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012427A1 true AR012427A1 (en) | 2000-10-18 |
Family
ID=8093298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980101722A AR012427A1 (en) | 1997-04-15 | 1998-04-15 | MODIFIED FTN-ALPHA MOLECULES, CODED DNA AND VACCINES INCLUDING SUCH FTN-ALPHA AND DNA MODIFICATION |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7118750B1 (en) |
| EP (1) | EP0975668B1 (en) |
| JP (1) | JP2001521386A (en) |
| KR (1) | KR100522289B1 (en) |
| CN (1) | CN1178955C (en) |
| AR (1) | AR012427A1 (en) |
| AT (1) | ATE326481T1 (en) |
| AU (1) | AU743400B2 (en) |
| BR (1) | BR9811462A (en) |
| CA (1) | CA2289476A1 (en) |
| CZ (1) | CZ9903657A3 (en) |
| DE (1) | DE69834556T2 (en) |
| DK (1) | DK0975668T3 (en) |
| EE (1) | EE9900461A (en) |
| ES (1) | ES2264569T3 (en) |
| HK (1) | HK1022918A1 (en) |
| HR (1) | HRP980203B1 (en) |
| HU (1) | HUP0001930A3 (en) |
| IL (1) | IL132281A0 (en) |
| NO (1) | NO995002L (en) |
| NZ (1) | NZ337955A (en) |
| PL (1) | PL194221B1 (en) |
| RU (1) | RU2241715C2 (en) |
| SI (1) | SI0975668T1 (en) |
| SK (1) | SK285639B6 (en) |
| TR (1) | TR199902562T2 (en) |
| TW (1) | TW510921B (en) |
| UA (1) | UA72440C2 (en) |
| WO (1) | WO1998046642A1 (en) |
| ZA (1) | ZA983148B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| CA2364026C (en) * | 1999-03-02 | 2012-08-21 | Centocor, Inc. | Anti-tnf.alpha. antibodies in therapy of asthma |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| HUP0201861A3 (en) | 1999-07-20 | 2004-07-28 | Pharmexa As | Method for down-regulating gdf-8 activity |
| AU2001265830A1 (en) * | 2000-06-21 | 2002-01-02 | Ferring, B.V. | Solubilised protein vaccines |
| AU2003208314A1 (en) * | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| FR2844514B1 (en) | 2002-09-16 | 2007-10-19 | Neovacs | STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES, COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| UA87453C2 (en) * | 2003-02-01 | 2009-07-27 | Вайет | Use a fragment ав for treatment of alzheimer's disease |
| WO2005084198A2 (en) | 2004-02-27 | 2005-09-15 | Vaxconsulting | Peptides of il1 beta and tnf alpha and method of treatment using same |
| JP2008523815A (en) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | Humanized amyloid beta antibody for use in improving cognition |
| CA2608728A1 (en) | 2005-05-16 | 2006-11-23 | Abbott Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| WO2009040361A1 (en) * | 2007-09-25 | 2009-04-02 | Intervet International B.V. | Vaccine for the treatment of osteoarthritis |
| JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| JP6292748B2 (en) | 2009-11-05 | 2018-03-14 | ザ ユーエービー リサーチ ファンデーション | Treatment of basal cell-like genotype cancer |
| WO2011116344A2 (en) | 2010-03-18 | 2011-09-22 | The Uab Research Foundation | Targeting cancer stem cells |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2648746A1 (en) | 2010-12-08 | 2013-10-16 | Neovacs | Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof |
| EP2462950A1 (en) | 2010-12-08 | 2012-06-13 | Neovacs | Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof |
| CN102539778A (en) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha |
| JP2011201902A (en) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | Active immunization to generate antibody to soluble a-beta |
| CN103376327A (en) * | 2012-04-28 | 2013-10-30 | 通用电气公司 | Method for detecting concentration of antibody or fusion protein |
| WO2016179430A1 (en) | 2015-05-05 | 2016-11-10 | Rubicon Biotechnology Llc | Cancer immunotherapeutic |
| CN106279403B (en) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | A kind of composition, kit and method detecting natural lung cancer associated antibodies |
| CN106478802B (en) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α protein B cell epitope, multi-antigen peptide containing this epitope and application |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0251037B1 (en) * | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Novel human TNF polypeptide mutants and DNAs encoding said mutants |
| DE3843534A1 (en) * | 1988-12-23 | 1990-07-12 | Basf Ag | NEW TNF POLYPEPTIDES |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU634379B2 (en) | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
| SE9102808L (en) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | VACCIN, HOW TO USE HUMAN USE, WILL BE INTENDED TO EFFECT THE SYMPTOMS OR PREVENT THE RISE OF IGE-MEDIATED ALLERGIC REACTIONS |
| CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| DK96493D0 (en) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | PROCEDURE FOR INDUCING ANTIBODY RESPONSE TO SELF-PROTEINS AND AUTOVACCINE PROCESSED BY THE PROCEDURE |
-
1998
- 1998-04-15 AT AT98916866T patent/ATE326481T1/en not_active IP Right Cessation
- 1998-04-15 EE EEP199900461A patent/EE9900461A/en unknown
- 1998-04-15 CZ CZ19993657A patent/CZ9903657A3/en unknown
- 1998-04-15 TR TR1999/02562T patent/TR199902562T2/en unknown
- 1998-04-15 UA UA99116210A patent/UA72440C2/en unknown
- 1998-04-15 IL IL13228198A patent/IL132281A0/en unknown
- 1998-04-15 PL PL98336295A patent/PL194221B1/en not_active IP Right Cessation
- 1998-04-15 ZA ZA9803148A patent/ZA983148B/en unknown
- 1998-04-15 WO PCT/DK1998/000157 patent/WO1998046642A1/en not_active Application Discontinuation
- 1998-04-15 EP EP98916866A patent/EP0975668B1/en not_active Expired - Lifetime
- 1998-04-15 AR ARP980101722A patent/AR012427A1/en unknown
- 1998-04-15 CN CNB988042142A patent/CN1178955C/en not_active Expired - Fee Related
- 1998-04-15 DE DE69834556T patent/DE69834556T2/en not_active Expired - Fee Related
- 1998-04-15 RU RU99122686/13A patent/RU2241715C2/en not_active IP Right Cessation
- 1998-04-15 DK DK98916866T patent/DK0975668T3/en active
- 1998-04-15 JP JP54338798A patent/JP2001521386A/en active Pending
- 1998-04-15 SI SI9830845T patent/SI0975668T1/en unknown
- 1998-04-15 HU HU0001930A patent/HUP0001930A3/en unknown
- 1998-04-15 ES ES98916866T patent/ES2264569T3/en not_active Expired - Lifetime
- 1998-04-15 BR BR9811462-0A patent/BR9811462A/en not_active Application Discontinuation
- 1998-04-15 KR KR10-1999-7009504A patent/KR100522289B1/en not_active IP Right Cessation
- 1998-04-15 CA CA002289476A patent/CA2289476A1/en not_active Abandoned
- 1998-04-15 US US09/060,294 patent/US7118750B1/en not_active Expired - Fee Related
- 1998-04-15 SK SK1409-99A patent/SK285639B6/en unknown
- 1998-04-15 AU AU70303/98A patent/AU743400B2/en not_active Ceased
- 1998-04-15 NZ NZ337955A patent/NZ337955A/en unknown
- 1998-04-15 HR HR980203A patent/HRP980203B1/en not_active IP Right Cessation
- 1998-07-20 TW TW087111808A patent/TW510921B/en not_active IP Right Cessation
-
1999
- 1999-10-14 NO NO995002A patent/NO995002L/en not_active Application Discontinuation
-
2000
- 2000-03-23 HK HK00101819A patent/HK1022918A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012427A1 (en) | MODIFIED FTN-ALPHA MOLECULES, CODED DNA AND VACCINES INCLUDING SUCH FTN-ALPHA AND DNA MODIFICATION | |
| CN104470943B (en) | New peptide and application thereof | |
| AR062895A1 (en) | COMPOSITIONS AND METHODS RELATED TO GLUCAGON RECEIVING ANTIBODIES | |
| ES2199941T3 (en) | MONOCLONAL ANTIBODIES AGAINST THE INTERFERONE RECEIVER, WITH NEUTRALIZING ACTIVITY AGAINST THE TYPE J INTERFERON. | |
| AR075047A1 (en) | METHODS AND COMPOSITIONS BASED ON PROTEIN TYPE 2 OF THE SHIGA TOXIN. PURIFIED POLYPEPTIDE. ANT-STX2 ANTIBODY. KIT | |
| AR046877A1 (en) | MUTEINS OF THE FIBROBLAST GROWTH FACTOR 21 | |
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| AR045710A1 (en) | USE OF TNF ALFA INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM FOR LOW DOSE TREATMENT | |
| AR066848A1 (en) | POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS OF THE TYPE 1 RECEPTOR OF THE TUMOR NECROSIS FACTOR (TNFR1) | |
| UY23327A1 (en) | PROCESS FOR THE PREPARATION OF HUMAN MUTEIN FROM THE TUMOR NECROSIS FACTOR | |
| AR080229A1 (en) | FIBRONECTINE ARMAZON DOMAIN PROTEINS THAT JOIN IL -23 (INTERLEUCINE 23) | |
| CO5700785A2 (en) | NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCAL DISEASE | |
| PT96230B (en) | PROCESS FOR THE PRODUCTION OF A POLIPEPTIDEO AND ANTAGONIST ANTIGONISTS OF HUMAN INTERLEUQUIN-4 | |
| ES2730050T3 (en) | Interleukin 38 truncated at terminal end N | |
| AR008387A1 (en) | NEW 5-PHENOXIALKYL-THIAZOLIDIN-2,4-DIONES, PROCEDURES FOR OBTAINING THEM, NEW INTERMEDIATE COMPOUNDS OF THESE PROCEDURES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE NEW 5-PHENOXIALKYL-TIAZOLIDIN- 2,4-DIAZES | |
| Waterston et al. | TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model | |
| Fernandes et al. | Recombinant T‐cell epitope conjugation: a new approach for Dermatophagoides hypoallergen design | |
| Zhang et al. | Interleukin-34 aggravates the severity of arthritis in collagen-induced arthritis mice by inducing interleukin-17 production | |
| BR122012018280B8 (en) | pharmaceutical composition comprising human luteinizing hormone and sucrose | |
| AU2005308411A1 (en) | Antigenic epitopes of interleukin-21, related antibodies and their use in medical field | |
| RU2004134331A (en) | MUC1 ANTIGEN WITH REDUCED NUMBER OF REPEATING VNTR BLOCKS | |
| Ptitsyn | Invariant features of globin primary structure and coding of their secondary structure | |
| Husby et al. | New, third class of amyloid fibril protein | |
| US6090378A (en) | Composition comprising interleukin-2 and thymidine kinase for the treatment of tumors | |
| ES2091752T3 (en) | MEANS AND PROCEDURE FOR OBTAINING A HUMAN ALPHA INTERLEUKIN-1 POLYPEPTIDE, RECOMBINANT. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |